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Many natural transmissible spongiform encephalopathy (TSE) infections are likely to be acquired periph-
erally, and studies in mice show that skin scarification is an effective means of scrapie transmission. After
peripheral exposure, TSE agents usually accumulate in lymphoid tissues before spreading to the brain. The
mechanisms of TSE transport to lymphoid tissues are not known. Langerhans cells (LCs) reside in the
epidermis and migrate to the draining lymph node after encountering antigen. To investigate the potential role
of LCs in scrapie transportation from the skin, we utilized mouse models in which their migration was blocked
either due to CD40 ligand deficiency (CD40L/ mice) or after caspase-1 inhibition. We show that the early
accumulation of scrapie infectivity in the draining lymph node and subsequent neuroinvasion was not impaired
in mice with blocked LC migration. Thus, LCs are not involved in TSE transport from the skin. After
intracerebral inoculation with scrapie, wild-type mice and CD40L/mice develop clinical disease with similar
incubation periods. However, after inoculation via skin scarification CD40L/ mice develop disease signifi-
cantly earlier than do wild-type mice. The shorter incubation period in CD40L/ mice is unexpected and
suggests that a CD40L-dependent mechanism is involved in impeding scrapie pathogenesis. In vitro studies
demonstrated that LCs have the potential to acquire and degrade protease-resistant prion protein, which is
thought to be a component of the infectious agent. Taken together, these data suggest that LCs are not involved
in scrapie transport to draining lymphoid tissues but might have the potential to degrade scrapie in the skin.
The transmissible spongiform encephalopathies (TSEs; or
prion diseases) are a group of infectious, fatal, neurodegen-
erative diseases, which affect both animals and humans. During
disease, PrPSc, an abnormal, detergent-insoluble, relatively
proteinase-resistant isoform of the host glycoprotein PrPC (38)
accumulates in infected tissues. The deposition of PrPSc within
the brains of most TSE-affected hosts is usually accompanied
with the development of neuropathological changes, such as
vacuolation, gliosis, and neuronal loss. Although the precise
nature of the TSE agent is not known, PrPSc accumulates with
infectivity in infected tissues and is considered to be a major or
possibly the sole component of the infectious agent (44).
Many TSEs, including natural sheep scrapie, bovine spongi-
form encephalopathy (BSE), chronic wasting disease in mule
deer and elk, and variant Creutzfeldt-Jakob disease (vCJD) in
humans, are acquired by peripheral exposure. For example, the
consumption of BSE-contaminated meat products by humans
is most likely responsible for the emergence of vCJD (7, 22).
Although many natural TSE infections are likely to be ac-
quired orally, studies in mice show that skin scarification is also
an effective means of scrapie transmission (51). This suggests
some natural TSE cases might be transmitted through skin
lesions in the mouth (3) or through sites of skin trauma during
close contact with infected animals. The potential to transmit
vCJD in humans iatrogenically during surgical or dental pro-
cedures is a current concern.
Early PrPSc accumulation takes place on follicular dendritic
cells (FDCs) within germinal centers in lymphoid tissues of
patients with vCJD (21), in mule deer with chronic wasting
disease (47), in sheep with natural scrapie (55), and in rodents
inoculated with scrapie by peripheral routes (6, 33, 37). In
mouse scrapie models, mature FDCs are critical for scrapie
replication and PrPSc accumulation in lymphoid tissues and, in
their absence, neuroinvasion after peripheral challenge is sig-
nificantly impaired (6, 32, 39, 51). From the lymphoid tissues,
scrapie is translocated to the central nervous system (CNS) via
peripheral nerves (20, 42).
Scrapie neuroinvasion after inoculation into the skin does
not occur through direct uptake by nerves in the skin since
highly immunodeficient SCID mice are refractory to scrapie
when inoculated by this route (51). These data confirm that
after inoculation via the skin, neuroinvasion occurs after accu-
mulation in lymphoid tissues as demonstrated after inoculation
by other peripheral routes (6, 34). How TSE agents are initially
transported from the site of exposure, such as the gastrointes-
tinal tract or the skin, to the germinal centers in which they
replicate is not known. FDCs could directly trap cell-free PrPSc
or other agent-associated molecules in a complement-bound
complex (28, 31), but it is also possible that mobile cells trans-
port the agent to lymphoid follicles. Several cells have the
potential to transport TSE agents, including macrophages and
migratory bone marrow-derived dendritic cells (DCs). The ev-
idence that macrophages destroy infectivity and degrade PrPSc
makes them an unlikely and inefficient transport candidate (4,
10, 11). Migratory bone marrow-derived DCs are a distinct
lineage from tissue-fixed, stroma-derived FDCs, which are not
considered to be of hemopoietic origin (14, 25). These DCs
continually circulate throughout the host’s tissues and tissue
fluids, where they sample antigens and transport them to lym-
phoid tissues (2). Unlike macrophages, DCs can retain some
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protein antigens in native, nondegraded form (57). A subpopu-
lation of these migratory DCs has been shown to transport
intestinally injected PrPSc to mesenteric lymph nodes via the
lymph (23), but direct demonstration of their involvement in
TSE pathogenesis is lacking.
Langerhans cells (LCs) are a subset of migratory DCs that
reside in the epidermis and migrate to the draining lymph node
following antigen encounter (2). DCs, including LCs, are con-
sidered to provide potential mechanisms for the transmission
of some pathogens into the skin such as dengue virus (56),
human immunodeficiency virus (45), maedi-visna lentivirus
(46), and Venezuelan equine encephalitis virus (35). These
characteristics suggested to us that LCs are plausible candi-
dates for scrapie transport from the skin to draining lymph
nodes. LCs require a number of stimuli to induce their mobi-
lization out of the skin (2). The CD40-CD40L signaling path-
way is just one component in a complex network of stimuli that
regulate the migration of antigen-bearing LCs out of the epi-
dermis to the draining lymph node (40). In mice deficient in
CD40 ligand (CD40L/ mice), the number and morphology
of LCs in the epidermis is normal, but they fail to migrate from
the skin and do not accumulate in the draining lymph node
(40). Likewise, caspase-1 plays an important role in the regu-
lation of LC migration, and its specific inhibition blocks LC
migration from the epidermis (1). In order to investigate the
potential role of LCs in scrapie transportation from skin to
draining lymphoid tissues, we studied pathogenesis in models
in which the migration of these cells from the epidermis was
impaired, either due to CD40L deficiency (40) or to caspase-1
inhibition (1). We used these models to investigate the poten-
tial role of LCs in scrapie pathogenesis after inoculation via the
skin with doses of scrapie equivalent to and much lower than
those previously shown to require amplification in lymphoid
tissues prior to neuroinvasion (31, 32, 51).
MATERIALS AND METHODS
Mice. CD40 ligand-deficient (CD40L/) mice (58) were bred and maintained
on the C57BL/6 background. Age- and sex-matched C57BL/6 mice were used as
wild-type control mice in studies with CD40L/ mice. Another subline of
C57BL mice, C57BL/Dk mice, were used in all other studies. All mice were
housed under specific-pathogen-free conditions.
Scrapie inoculation. Mice (8 to 12 weeks of age) were inoculated with the
ME7 scrapie strain by skin scarification of the medial surface of the right thigh.
Briefly, prior to scarification 1 cm2 of hair covering the scarification site was
trimmed by using curved scissors and then removed completely with an electric
razor. After 24 h a 23-gauge needle was used to create a 5-mm abrasion in the
epidermal layers of the skin at the scarification site. Care was taken to avoid
damage to the dermis or drawing blood during scarification. Then, by using a
26-gauge needle, one droplet (6 l) of ME7 scrapie mouse brain homogenate
containing ca. 104 or 103 50% infectious dose (ID50) units was applied to the
abrasion and worked into the site by using sweeping strokes. The scarification
site was then sealed with OpSite (Smith & Nephew Medical, Ltd., Hull, United
Kingdom) and allowed to dry before the animals were returned to their final
holding cages. Where indicated, separate groups of mice were inoculated by
intracerebral (i.c.) injection with 20 l of scrapie mouse brain homogenate
containing ca. 104.5 ID50 units as a titer control. After challenge, animals were
coded, assessed weekly for signs of clinical disease, and killed at a standard
clinical endpoint (17). Scrapie diagnosis was confirmed by histopathologic as-
sessment of TSE vacuolation in the brain. For the construction of lesion profiles,
vacuolar changes were scored in nine gray-matter and three white-matter areas
of the brain as described previously (18).
Where indicated, some mice were sacrificed 49 days postinoculation, and
spleens and inguinal lymph nodes (ILNs) taken for further analysis. For bioassay
of scrapie infectivity, two half spleens were pooled from each group and prepared
as 10% (wt/vol) homogenates in physiological saline. Likewise, the ILNs draining
the inoculation site were pooled from two mice and prepared as a 10% (wt/vol)
homogenate. Groups of 12 C57BL/Dk indicator mice were injected i.c. with 20 l
of each homogenate. The scrapie titer in each sample was determined from the
mean incubation period in the assay mice by reference to established dose-
incubation period response curves for scrapie-infected spleen tissue.
Caspase inhibitor treatment. Where indicated, prior to inoculation with
scrapie by skin scarification, groups of C57BL/Dk mice were pretreated at the
shaved inoculation site with 50 l of 0.4 mM caspase-1 inhibitor II (Ac-YVAD-
cmk; Calbiochem, Beeston, United Kingdom), 0.4 mM caspase-3 inhibitor III
(Ac-DEVD-cmk; Calbiochem), or vehicle alone (dimethyl sulfoxide [DMSO]) by
using a previously established protocol (1). One hour later, mice were inoculated
with scrapie as described above. Care was taken to ensure that the scrapie
inoculum was only applied to the pretreated area of skin.
Immunohistochemical analysis. To monitor FDC status, spleen halves were
snap-frozen at the temperature of liquid nitrogen. Serial frozen sections (thick-
ness, 10 m) were cut on a cryostat, and FDCs were visualized by staining with
either the FDC-specific rat monoclonal antiserum FDC-M2 (AMS Biotechnol-
ogy, Oxon, United Kingdom) or 8C12 monoclonal antiserum to detect CD35
(BD Biosciences Pharmingen, Oxford, United Kingdom). B lymphocytes were
detected by using the rat B220 monoclonal antiserum to detect CD45R (Caltag,
Towcester, United Kingdom) or biotin-conjugated peanut agglutinin (PNA;
Sigma, Poole, United Kingdom) to detect germinal center B lymphocytes. Im-
munolabeling was carried out with alkaline phosphatase coupled to the avidin-
biotin complex (Vector Laboratories, Burlingame, Calif.). Vector Red (Vector
Laboratories) was used as a substrate.
For the detection of PrP in the brain, tissues were fixed in periodate-lysine-
paraformaldehyde and embedded in paraffin wax. Sections (thickness, 6 m)
were deparaffinized and then pretreated to enhance PrP immunostaining by
hydrated autoclaving (15 min, 121°C, hydration) and subsequent immersion in
formic acid (98%) for 5 min (37). Sections were then stained with the PrP-
specific monoclonal antiserum 6H4 (Prionics, Zurich, Switzerland), and immu-
nolabeling was detected by using hydrogen peroxidase coupled to the avidin-
biotin complex (Vector Laboratories) with diaminobenzidine as a substrate.
Glial fibrillary acid protein (GFAP) was detected on adjacent brain sections by
using rabbit GFAP-specific antiserum (Dako, Ltd., Ely, United Kingdom), and
immunolabeling carried out by using alkaline phosphatase coupled to the avidin-
biotin complex by using Vector Red as a substrate. Microglia were detected by
staining with biotin-conjugated Lycopersicon esculentum agglutinin (LEA;
Sigma), and specific labeling was detected by using hydrogen peroxidase coupled
to the avidin-biotin complex with diaminobenzidine as a substrate.
All sections were counterstained with hematoxylin to distinguish cell nuclei.
Immunoblot detection of PrPSc. Individual spleen fragments or ILNs were
prepared as previously described (15). Briefly, before immunoblot analysis, tissue
homogenates were treated in the absence or presence of 80 g of proteinase K
(to confirm the presence of PrPSc), electrophoresed through sodium dodecyl
sulfate–10 to 20% polyacrylamide gels (Bio-Rad, Hemel Hempstead, United
Kingdom), and transferred to polyvinylidene difluoride membranes (Bio-Rad) by
semidry blotting. PrP was detected with the PrP-specific mouse monoclonal
antiserum 8H4 (61). Immunolabeling was carried out with horseradish peroxi-
dase-conjugated goat anti-mouse immunoglobulin G antiserum (Jackson Immu-
noresearch Laboratories, Inc., West Grove, Pa.), and bound horseradish perox-
idase activity was detected with Supersignal West Dura Extended Duration
Substrate (Pierce, Chester, United Kingdom).
Cell culture. The XS106 and XS52 cell lines (54, 59) are long-term DC lines
established from the epidermis of newborn A/J mice and BALB/c mice, respec-
tively. XS106 cells were expanded and maintained in complete RPMI 1640 (60)
supplemented with 0.5 ng of recombinant murine granulocyte monocyte colony-
stimulating factor (R&D Systems, Abingdon, United Kingdom)/ml and 5% (vol/
vol) NS47 fibroblast culture supernatant. XS52 cells were expanded and main-
tained in complete RPMI 1640 supplemented with 2.0 ng of recombinant murine
granulocyte monocyte colony-stimulating factor/ml and 10% (vol/vol) NS47 fi-
broblast culture supernatant/ml. Both cell lines were cultivated at 37°C in a 5%
CO2–air atmosphere. For scrapie inoculation studies, sterile coverslips were
placed in the wells of a 24-well plate (Corning, Buckinghamshire, United King-
dom). Cells (5  105 in 1 ml of medium) were seeded into each well. When
confluent (ca. 2  106 cells per coverslip), each well was then inoculated with 10
l of 10% (wt/vol) terminal scrapie mouse brain homogenate in complete RPMI
(equivalent to 1.0 mg of tissue). Duplicate sets of cultures cells were inoculated
with 10 l of 10% (wt/vol) uninfected mouse brain homogenate in complete
RPMI as a control. The medium was removed after 16 h of incubation at 37°C
in a 5% CO2–air atmosphere, and cells in each well were washed extensively with
fresh medium by pipetting. The cells were then incubated at 37°C for the times
VOL. 79, 2005 LANGERHANS CELL-INDEPENDENT NEUROINVASION BY SCRAPIE 1889
indicated before being assayed for PrPSc accumulation by the cell blot procedure
(5). Briefly, coverslips were removed, and the cell-containing side was blotted
onto polyvinylidene difluoride membranes, treated with proteinase K, denatured
with guanidine isothiocyanate, and PrP detected by using the PrP-specific mouse
monoclonal antiserum 8H4 (61). Immunolabeling was carried out with horse-
radish peroxidase-conjugated goat anti-mouse IgG antiserum (Jackson Immu-
noresearch Laboratories), and bound horseradish peroxidase activity was de-
tected with Supersignal West Dura Extended Duration Substrate (Pierce). After
exposure, membranes were stained with 0.5 g of ethidium bromide/ml and
observed in UV light to confirm transfer of the cell layer (13). Cell viability was
assessed in duplicate sets of cultures by trypan blue dye exclusion, and metabolic
activity was measured by using Alamarblue (Serotec, Oxford, United Kingdom).
Statistical analysis. Where indicated, the incubation periods are presented as
mean (days)  the standard error of the mean. Significant differences between
incubation periods in different groups were determined by one-way analysis of
variance (ANOVA) with Minitab for Windows software (Minitab, Inc., State
College, Pa.).
RESULTS
Effect of caspase-1 inhibition on scrapie pathogenesis. Pre-
vious studies have shown that topical treatment with a phar-
macological inhibitor of caspase-1 potently blocks LC migra-
tion from the skin (1). Therefore, we investigated whether the
accumulation of scrapie in the draining lymph node was af-
fected after topical caspase-1 inhibition. Prior to inoculation
with scrapie by skin scarification (6 l containing ca. 104 ID50
units), C57BL/Dk mice were treated at the inoculation site
with Ac-YVAD-cmk, a cell-permeable, irreversible caspase-1
inhibitor (19, 53), according to a previously established proto-
col (1). This treatment effectively and irreversibly blocks both
spontaneous and induced LC migration from the epidermis
(1). Control pretreatments included application of Ac-DEVD-
cmk, a specific inhibitor of caspase-3 that has little effect on
caspase-1 (19), vehicle alone (DMSO), or no pretreatment.
After peripheral inoculation of immunocompetent mice with
the ME7 scrapie strain, high levels of infectivity accumulate in
lymphoid tissues within the first few weeks postinoculation and
are maintained throughout the course of infection (6, 33). Our
studies suggest that after inoculation via skin scarification, the
infectivity levels in the draining ILNs begin to peak around 49
days postinoculation and subsequently plateau (unpublished
data). Therefore, in the present study, ILNs draining the site of
inoculation were taken from two mice from each treatment
group 49 days after inoculation and scrapie infectivity titers in
pooled (n  2) tissue homogenates were estimated by bioassay
in indicator mice. As expected, ILNs from untreated mice
contained high levels of scrapie infectivity (ca. 6.7 log i.c. ID50/
g). If we assume that analyses of scrapie infectivity in indicator
mice have a standard deviation of 0.5 log i.c. ID50/g, this
margin of error was used as a threshold above or below which
differences between samples were considered significant. How-
ever, our studies clearly demonstrated that infectivity titers in
ILNs from Ac-YVAD-cmk-pretreated mice (ca. 6.4 log i.c.
ID50/g) were similar to those from untreated mice, indicating
that pharmacological blockade of caspase-1-dependent LC mi-
gration from the skin did not affect the early accumulation of
scrapie infectivity in ILNs. Likewise, no effect on the early
accumulation of scrapie infectivity in ILNs was observed in
mice pretreated with Ac-DEVD-cmk or DMSO alone as con-
trols compared to Ac-YVAD-cmk-pretreated mice or un-
treated control mice. Tissues from mice treated with DEVD-
cmk or DMSO alone each contained infectivity titers of ca. 6.0
log i.c. ID50/g. Consistent with the finding that caspase-1 inhi-
bition did not affect the early accumulation of scrapie in lymph
nodes after inoculation via skin scarification, Ac-YVAD-cmk
pretreatment did not significantly affect the incubation period
or disease susceptibility compared to untreated control mice (P
 0.192, n  9 [ANOVA]). Likewise, treatment of mice with
the control reagents Ac-DEVD-cmk or DMSO alone also did
not significantly affect the incubation period or disease suscep-
tibility compared to untreated control mice (P 0.774 [n 10]
and P  0.148 [n  10], respectively [ANOVA]). Mice from
each treatment group developed clinical scrapie with similar
incubation periods between 316 and 323 days (Table 1).
Lymphoid tissues of CD40L/ mice contain FDCs but lack
germinal centers. We next investigated scrapie pathogenesis in
mice with a permanent block in LC migration out of the skin
due to a targeted deletion of the CD40L gene (CD40L/
mice [40]). CD40L/ mice are incapable of mounting T-cell-
dependent humoral immune responses, and germinal center
development is impaired (58). Therefore, FDC status was first
assessed in spleens from C57BL/6 wild-type mice and
CD40L/ mice. Germinal centers containing PNA-binding B
lymphocytes were detected in the spleens of all C57BL/6 wild-
type mice but not in the spleens of CD40L/ mice (Fig. 1a).
Despite the impaired germinal center formation in the lym-
phoid tissues of CD40L/ mice, mature FDC networks sur-
rounded by B lymphocytes (CD45R/B220 positive cells) were
detected (Fig. 1b). Expression of the markers FDC-M2 and
CD35 by FDCs in spleens of CD40L/ mice appeared to be
similar to that observed in lymphoid tissues from C57BL/6
wild-type mice (Fig. 1b).
Effect of CD40L deficiency on scrapie accumulation in lym-
phoid tissues. We next studied the early delivery of scrapie
from the skin to the draining lymphoid tissues in the absence of
migratory LCs in CD40L/ mice. In the present study, ILNs
draining the site of inoculation and spleens were taken from
two wild-type mice and from two CD40L/ mice 49 days after
inoculation with scrapie by skin scarification (6 l containing
ca. 104 ID50 units). The scrapie infectivity titers in pooled (n 
2) tissue homogenates were estimated by bioassay in groups of
12 indicator mice. As expected, draining ILNs from wild-type
TABLE 1. Treatment of skin with the caspase-1 inhibitor Ac-
YVAD-cmk to block LC migration prior to scrapie inoculation by
skin scarification does not affect disease susceptibilitya
Pretreatmentb Incidencec Mean incubationperiod (days)  SE
Statistical
analysisd
None 9/9 316 2
DMSO 10/10 323 4 0.186
Ac-YVAD-cmk 14/14 323 4 0.192
Ac-DEVD-cmk 10/10 316 3 0.774
a C57BL/Dk mice were inoculated with the ME7 scrapie strain (104 ID50 units)
by skin scarification of the medial surface of the right thigh.
b Prior to scrapie inoculation mice were pretreated at the shaved inoculation
site with Ac-YVAD-cmk (a caspase-1 inhibitor) or Ac-DEVD-cmk (a caspase-3
inhibitor) or vehicle alone (DMSO) as controls.
c That is, the number of animals affected/the total number of animals inocu-
lated.
d Degrees of significance between the mean incubation periods for each treat-
ment group compared to untreated control mice (None) were determined by
ANOVA. Values represent P values, where P  0.05 was considered significant
different.
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mice contained high levels of scrapie infectivity (ca. 5.8 log i.c.
ID50/g). Again, to compare infectivity titers between groups, a
standard deviation of 0.5 log i.c. ID50/g was used as a thresh-
old above or below which samples were considered signifi-
cantly different. Our data suggested that in the absence of
efficient LC migration from the skin the early accumulation of
scrapie infectivity in the draining ILN was not impaired, since
high levels of infectivity were also detected in samples of ILNs
from CD40L/ mice taken 49 days postinoculation (ca. 5.9
log i.c. ID50/g).
Only trace levels of infectivity (2.0 log i.c. ID50/g) were
detected in pooled spleen samples from the same wild-type
mice and CD40L/ mice taken 49 days postinoculation. How-
ever, at the terminal stage of disease, abundant detergent-
insoluble, relatively proteinase K-resistant accumulations of
disease-specific PrPSc were detected in spleens from wild-type
mice (Fig. 2, lanes 2 and 4) and CD40L/ mice (Fig. 2, lanes
6 and 8). Taken together, these data demonstrate that after
inoculation via the skin, infectivity is propagated to the drain-
ing lymph node via the lymphatics in an LC-independent man-
ner and subsequently distributed to the spleen, probably via
the bloodstream. Since only trace levels of infectivity are mea-
sured in the spleen at a time when high levels of infectivity are
detected in the draining lymph node, these data suggest that
the initial transmission from the skin to local lymphoid tissues
does not occur via the bloodstream.
Susceptibility of CD40L/ mice to scrapie infection. When
mice were challenged i.c. with a moderate dose of scrapie
(104.5 ID50 units), wild-type mice and CD40L
/ mice devel-
oped clinical signs of scrapie with similar incubation periods of
159 to 165 days (Table 2). Histopathologic analysis of brain
tissue from terminally affected wild-type and CD40L/ mice
displayed the characteristic spongiform pathology, disease-spe-
cific PrP accumulation, and reactive astrocytes expressing the
high levels of GFAP typical of an i.c. inoculation with the ME7
scrapie strain, although microglia activation appeared more
pronounced in the brains of CD40L/ mice (data not shown).
However, the severity and distribution of pathological vacuo-
lation in the brain was not significantly different between
mouse strains (Fig. 3a). Thus, these data suggest that the
CD40L signaling pathway is not involved in the cerebral patho-
genesis of the ME7 scrapie strain.
After inoculation with scrapie by skin scarification,
CD40L/ mice developed clinical disease significantly earlier
than immunocompetent wild-type mice (Table 2). For exam-
ple, following inoculation with a moderate dose of scrapie (104
ID50 units), all immunocompetent wild-type mice developed
clinical signs of scrapie with a mean incubation period of 344
5 days (n  8). In contrast, CD40L/ mice developed clinical
scrapie 32 days earlier than the wild-type controls, with a mean
incubation period of 312  5 days (P  0.0003, n  9
[ANOVA]). Characteristic spongiform pathology and disease-
FIG. 1. Germinal center architecture in the spleens of C57BL/6
wild-type (WT) and CD40L/ mice. (a) Immunohistochemical anal-
ysis detected the presence of PNA-positive germinal center B lympho-
cytes in the spleens of WT mice (red; left panel) but not in tissue from
CD40L/ mice (right panel). Magnification, 100. (b) Immunohis-
tochemical analysis of FDC networks in spleen tissue from wild-type
(left panels) and CD40L/ mice (right panels). Adjacent frozen sec-
tions were stained with FDC-M2 (upper row; red) monoclonal anti-
serum to detect FDCs, 8C12 monoclonal antiserum to detect CD35
(middle row; red), and B220 monoclonal antiserum to detect B lym-
phocytes (lower row; red). Magnification, 200. All sections were
counterstained with hematoxylin (blue).
FIG. 2. PrPSc accumulation in spleen tissue from terminally
scrapie-infected C57BL/6 wild-type (WT) and CD40L/ mice inocu-
lated with scrapie by skin scarification. Immunoblots show the accu-
mulation of detergent-insoluble, relatively proteinase K-resistant
PrPSc. The treatment of tissues in the presence () or absence () of
proteinase K prior to electrophoresis is indicated. After proteinase K
treatment, a typical three-band pattern was observed between the
molecular mass values of 20 and 30 kDa, representing the unglycosy-
lated, monoglycosylated, and diglycosylated isomers of PrP (in order of
increasing molecular mass). PK, proteinase K.
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specific PrP accumulations typical of an infection with the ME7
scrapie strain were detected in the brains of all peripherally
inoculated wild-type and CD40L/ mice (Fig. 4). Although
the activation status of LEA-binding microglia appeared more
pronounced in the brains of CD40L/ mice compared to
wild-type mice (Fig. 4), no significant difference in the severity
or distribution of the vacuolation in the brain was observed
between mouse strains (Fig. 3b). Thus, the shortened incuba-
tion period in CD40L/ mice was unlikely to be attributed to
an exaggerated neuropathology in these mice compared to
wild-type mice. After peripheral inoculation with a limiting
dose of scrapie (103 ID50 units), CD40L
/ mice also devel-
oped clinical scrapie sooner than wild-type mice (Table 2).
Although CD40L/ mice succumbed to scrapie after inocu-
lation with a limiting dose of scrapie with a mean incubation
period of 331  6 days (n  7), 24 days earlier than wild-type
mice (355  13 days, n  8), the difference between the two
groups in this instance was not significant (P  0.075
[ANOVA]). This is most likely a consequence of the wide
scatter of incubation periods for the wild-type mice from 336 to
439 days.
Skin-derived LC-like cells degrade PrPSc in vitro. A series of
long-term DC lines have been generated from murine skin that
retain important features of LCs (54, 59). In the present study,
we used the skin-derived LC-like cell lines XS106 and XS52.
The XS106 cells express moderate levels of Ia molecules,
CD40, CD80, and CD86 and are capable of stimulating im-
mune responses after adoptive transfer (54). Monolayers of
XS106 cells were inoculated with a suspension of terminally
ME7-scrapie infected brain tissue or normal brain tissue (as a
control). After 16 h of incubation, culture medium was aspi-
rated, and cells were washed extensively with fresh medium to
remove residual inoculum. Fresh medium was then added to
the monolayers, and cells were incubated for up to 96 h. The
experiment demonstrated that 24 h after inoculation with
scrapie, XS106 LC-like cells had acquired and retained high
levels of PrPSc (Fig. 5a). No PrPSc accumulations were de-
tected in association with cells exposed to normal brain ho-
mogenate as a control (Fig. 5a). As a further control, cell-free
coverslips were also exposed to scrapie-infected brain tissue
and treated as described above. No PrPSc was detected on
scrapie-exposed cell-free coverslips (data not shown), confirm-
ing that the PrPSc accumulations detected in Fig. 5a were cell
associated. Antigens acquired by DCs usually quickly enter the
lysosomal compartment, where they are broken down into
peptides for presentation to lymphocytes in association with
major histocompatibility complex class II (2). After extended
cultivation of XS106 LC-like cells with scrapie (up to 96 h), the
level of PrPSc detected in association with these cells appeared
to decline (Fig. 5a). No significant effect on cell viability or
metabolic activity was observed after exposure of the cells to
scrapie-brain homogenate compared to those exposed to nor-
mal brain homogenate or medium alone as controls (data not
shown). Thus, the reduction in the PrPSc associated with the
XS106 LC-like cells was unlikely to be due to reduced cell
viability.
In contrast to XS106 cells, XS52 cells are extremely “imma-
ture” in terms of their phenotype and function and have a poor
FIG. 3. Similar pathological targeting in the brains of terminally
scrapie-affected CD40L/ mice and C57BL/6 wild-type mice. Mice
were inoculated with the ME7 scrapie strain by i.c. injection (a) or via
skin scarification (b). Vacuolation in the brain was scored on a scale of
0 to 5 in the following gray-matter (G1 to G9) and white-matter (W1
to W3) areas: G1, dorsal medulla; G2, cerebellar cortex; G3, superior
colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; G7,
septum; G8, retrosplenial and adjacent motor cortex; G9, cingulate
and adjacent motor cortex; W1, inferior and middle cerebellar pe-
duncles; W2, decussation of superior cerebellar peduncles; W3, cere-
bral peduncles. Each point represents the mean vacuolation score 
the standard deviation for groups of five to nine mice. Symbols: F,
C57BL/6 wild-type mice; E, CD40L/ mice.
TABLE 2. Susceptibility of wild-type (C57BL/6) and CD40L/
mice to scrapie after inoculation via skin scarification or i.c.
injectiona
Mouse
strain
Skin scarificationb i.c. inoculation (10
4.5
ID50 units)
104 ID50 units 10
3 ID50 units
Scrapie
incidence
Incubation
periodScrapie
incidence
Incubation
period
Scrapie
incidence
Incubation
period
C57BL/6 8/8 344  5 8/9c 355  13 5/5 165  1
CD40L/ 9/10d 312  5 7/8e 331  6 6/6 159  1
a Scrapie incidence is expressed as the number of animals with scrapie/total
number of animals inoculated. The incubation period is expressed as the mean
number of days  the standard error of the mean.
b Mice were inoculated with the ME7 scrapie strain by skin scarification of the
medial surface of the right thigh.
c One mouse remained free from the signs of scrapie for 504 days postinocu-
lation, at which point the experiment was terminated. No histopathologic signs of
scrapie were detected in the brain (data not shown).
d One mouse died at 306 days postinoculation. No histopathologic signs of
scrapie were detected in the brain (data not shown).
e One mouse died at 359 days postinoculation. No histopathologic signs of
scrapie were detected in the brain (data not shown).
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capacity to initiate antigen-specific immune responses in living
animals (54, 59). In order to confirm that the ability of XS106
LC-like cells to degrade PrPSc was a property of cells with a
phenotype typical of LCs and not a property of all in vitro-
cultivated cell lines, parallel experiments were performed with
the highly immature LC-like cell line XS52 as a negative con-
trol. Although these additional experiments demonstrated
that, 24 h after inoculation with scrapie, XS52 LC-like cells had
acquired high levels of PrPSc (Fig. 5b), after 96 h cultivation
the level of PrPSc detected in association with these cells ap-
peared to be similar to that observed at 24 h (Fig. 5b). Thus,
taken together, these data suggest that “mature” XS106 LC-
like cells, in contrast to highly “immature” XS52 cells, have the
potential to acquire and degrade PrPSc.
DISCUSSION
In order to investigate the potential role of LCs in scrapie
transportation from the skin to the draining lymph node, we
utilized mouse models in which the migration of LCs from the
skin was blocked (1, 40). We show that pharmacological block-
ade of LC migration (1) by treatment with an irreversible
inhibitor of caspase-1 prior to inoculation with scrapie through
the skin did not impair the early accumulation of infectivity in
draining lymphoid tissue or delay subsequent neuroinvasion.
The migration of LCs from the skin is also blocked in
CD40L/ mice (40). The early accumulation of infectivity in
draining lymphoid tissues of these mice was likewise not im-
paired in the absence of LC migration from the skin. Together,
these data suggest that LCs are not involved in TSE transport
from the skin to lymphoid tissue. When wild-type mice and
CD40L/ mice were challenged with scrapie directly into the
CNS, both strains of mice developed clinical signs of scrapie
with similar incubation periods and exhibited similar CNS pa-
thology. In contrast, after inoculation via skin scarification the
disease incubation period was shorter in CD40L/ mice than
in wild-type mice. The shortened disease incubation period in
CD40L/ mice was unexpected and demonstrates that a
CD40L-dependent process involved in impeding scrapie neu-
roinvasion was disrupted due to CD40L deficiency. Since DCs
can process and degrade PrPSc in vitro (30), these data sug-
gested to us that LCs might degrade scrapie in the skin. To
address this, we exposed an epidermis-derived LC-like cell line
(59) to scrapie in vitro. Our data suggest that in vitro-cultivated
LCs are likewise able to acquire and degrade PrPSc. Taken
FIG. 4. Histological analysis of brain tissue from terminally scrapie-
infected C57BL/6 wild-type (WT; left panels) and CD40L/ mice (right
panels) inoculated with scrapie by skin scarification. Large PrP accumu-
lations (upper row; brown), reactive astrocytes expressing high levels of
GFAP (second row; red), and spongiform pathology (hematoxylin and
eosin; third row) were detected in the hippocampi of all mice that devel-
oped clinical signs of scrapie. Analysis of LEA-binding microglia (bottom
row; brown) suggested that their activation was more pronounced in
brains of CD40L/ mice compared to wild-type mice. All sections were
counterstained with hematoxylin (blue). Magnification, 100.
FIG. 5. Skin-derived LC-like cells degrade PrPSc in vitro. Mono-
layers of XS106 LC-like cells (a) or the highly immature cell line XS52
(b) were exposed to 10 l of 10% scrapie-infected brain homogenate
(scrapie) for 16 h. Duplicate sets of cultures were exposed to 10 l of
10% uninfected normal brain homogenate (NBr) as a control. Mono-
layers were then washed to remove residual homogenate and incu-
bated for the times indicated at 37°C in a 5% CO2–air atmosphere.
Levels of PrPSc associated with the cells were determined by cell
blotting (5). Treatment of membranes in the presence () or absence
() of proteinase K (PK) prior to immunostaining is indicated.
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together, our studies suggest that LCs are not involved in
scrapie transport to draining lymphoid tissue. However, these
cells might have the potential to acquire and degrade scrapie in
the skin.
TSE transport mechanisms from the site of exposure to the
germinal centers in which they replicate are not known. We
considered transport in association with migratory bone mar-
row-derived DCs a credible candidate mechanism since these
cells sample antigens in the periphery and transport them to
lymphoid tissues (2). DCs can also retain some protein anti-
gens in native, nondegraded form (57). Recent research has
demonstrated that bone marrow-derived DCs can acquire
PrPSc in vitro (23, 30) and that a subpopulation of migratory
DCs has the potential to transport intestinally injected PrPSc to
mesenteric lymph nodes via the lymph (23). Others have shown
that the prion protein fragment PrP106-126 is a chemoattractant
for monocyte-derived DCs (24). Despite these observations,
direct demonstration of the involvement of DCs in the initial
delivery of TSE agents to lymphoid tissues is lacking. Studies
by Oldstone et al. (41) have suggested CD11c DCs are not
involved in peripheral TSE pathogenesis. However, in that
study mice were inoculated with high doses of scrapie, which
have been shown consistently to bypass the need for replication
in lymphoid tissues in the same RML scrapie model (43) and
our own ME7 scrapie model (16). Here we investigated the
potential role of LCs in scrapie pathogenesis after inoculation
via the skin with doses of ME7 scrapie equivalent to (104 ID50
units) and much lower (103 ID50 units) than those we have
previously shown to require amplification in lymphoid tissues
prior to neuroinvasion (31, 32, 51).
The cytokines interleukin-1	 (IL-1	) and tumor necrosis
factor alpha (TNF-
) play key roles in regulating the migration
of LCs from the epidermis to the draining lymph node (12, 49).
LC migration from the epidermis is blocked following specific
inhibition of either of these cytokines (12). IL-1	 is synthesized
as an inactive 31-kDa precursor that is cleaved to release the
active 17-kDa IL-1	 molecule by the cysteine protease
caspase-1 (52). In mice deficient in caspase-1 LC migration
from the skin is impaired (1). Furthermore, treatment of skin
with Ac-YVAD-cmk, an irreversible inhibitor of caspase-1 (19,
53), potently blocks both spontaneous and induced LC migra-
tion from the skin (1). Our data show that blockade of LC
migration from the epidermis through treatment with Ac-
YVAD-cmk prior to inoculation with scrapie did not affect the
early accumulation of infectivity in draining ILNs since equally
high levels were detected in tissues from both control and
treated mice.
Treatment of mice with Ac-YVAD-cmk blocks induced LC
migration from the skin by ca. 67% (1). Thus, the possibility
that the magnitude of the Ac-YVAD-cmk-mediated inhibition
of LC migration was insufficient to observe a measurable effect
on pathogenesis deserves consideration. However, this hypoth-
esis relies on the assumption that the 67% reduction in LC
migration correlates directly to a 67% reduction in scrapie
delivery. Our studies suggest that only a small subpopulation of
intestinal DCs (0.5 to 5%) acquire and transport detectable
levels of PrPSc from the gut lumen (23). Thus, it is possible that
the majority of LC subpopulations, if involved in scrapie trans-
portation, may be retained within the 67% that cannot migrate
from the epidermis after Ac-YVAD-cmk treatment. After pe-
ripheral inoculation, it is likely that a portion of the inoculum
is destroyed by the actions of phagocytic cells before it has the
opportunity to begin replication in association with FDCs. The
effects of this on pathogenesis are likely to be dose dependent,
with small doses being more easily destroyed than higher
doses, in which a greater portion would be retained. If a 67%
reduction in LC migration did correlate directly to a 67%
reduction in the initial scrapie delivery, it is possible that a
further fraction may be degraded once it reached the draining
lymph node, further reducing the inoculum titer.
With the above points in mind we are confident that the
effects of Ac-YVAD-cmk-treatment on LC migration would be
sufficient to cause a measurable effect on scrapie pathogenesis
if these cells were involved. However, to further address this
important issue, a mouse model was used in which LC migra-
tion from the skin is permanently blocked. In CD40L/ mice,
the number and morphology of LCs in the epidermis was
normal but they did not migrate from the skin after stimulation
(40). The defect in LC migration in CD40L/ mice was as-
sociated with defective TNF-
 production in the skin (40).
When animals were inoculated with scrapie via the skin, high
levels of infectivity were also detected within the ILNs of
wild-type and CD40L/ mice 49 days postinoculation. Thus,
the early accumulation of scrapie in the draining lymphoid
tissue was not impaired in mice whose LCs cannot migrate out
of the epidermis. Therefore, these two approaches together
suggest that the initial transportation of scrapie from the skin
to draining lymphoid tissue occurs through an LC-independent
mechanism.
The time point at which the tissues were assayed for infec-
tivity accumulation is critical. If scrapie titers were to peak
much sooner than the time they are analyzed it may not be
possible to demonstrate a reduced early accumulation in mice
with blocked LC migration since sufficient time may have been
provided for a reduced scrapie dose to reach peak levels before
analysis. Our unpublished observations suggest that after in-
oculation with scrapie by skin scarification the infectivity levels
in the draining ILN begin to peak around 49 days postinocu-
lation and subsequently plateau. If the delivery of scrapie in-
fectivity to the draining lymph node was reduced in the ab-
sence of migratory LCs, these data suggest that it would have
been possible to demonstrate a reduced accumulation of in-
fectivity in draining ILNs 49 days after inoculation since infec-
tivity levels in tissues from control mice would only just have
started to approach peak levels.
Every effort was taken at the time of scarification to avoid
causing damage to the dermis or drawing blood to prevent the
leakage of infectivity into the bloodstream during inoculation.
If scrapie infectivity had leached into the bloodstream, a need
for LCs in transportation to lymphoid tissues would obviously
have been bypassed. Analysis of spleen tissue 49 days postin-
oculation failed to detect infectivity in tissues collected from
the same wild-type and CD40L/ mice. These data therefore
suggest that the initial transmission of scrapie from the skin to
lymphoid tissues does not occur via the bloodstream, which
would have resulted in a widespread dissemination of infectiv-
ity throughout the lymphoid system. Spleen tissue collected for
immunoblot analysis from terminally affected wild-type and
CD40L/ mice detected large accumulations of PrPSc. There-
fore, following inoculation via the skin, infectivity is first prop-
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agated to the draining lymph node via the lymphatics in an
LC-independent manner and subsequently distributed to the
spleen, probably via the bloodstream.
Mice deficient in CD40L are incapable of mounting T-lym-
phocyte-dependent humoral immune responses (58). Although
mature FDC networks surrounded by B cells were detected in
the spleens of CD40L/ mice, germinal centers containing
PNA-binding B lymphocytes were absent. After inoculation by
skin scarification CD40L/ mice accumulated levels of PrPSc
and infectivity in their lymphoid tissues comparable to wild-
type mice, despite an absence of germinal centers. Thus, the
absence of PNA-positive germinal centers in CD40L/ mice
does not affect the ability of their lymphoid tissues to accumu-
late PrPSc and infectivity after exposure to the ME7 scrapie
strain. These data are consistent with previous studies utilizing
IL-6/ mice that also have diminished germinal centers but
mature FDC networks in the spleen (29). After peripheral
inoculation with ME7 scrapie, spleens of IL-6/ mice accu-
mulated levels of PrPSc and scrapie infectivity comparable to
those in the spleens of wild-type mice and maintained these
levels for the duration of the disease (33). Since deficiencies in
T lymphocytes (26, 27) or circulating immunoglobulins (28) do
not affect scrapie pathogenesis, it is likewise unlikely that the
impaired T-lymphocyte-dependent humoral immune re-
sponses in CD40L/ mice (58) affect pathogenesis.
Congruent with the observation that the early accumulation
of scrapie infectivity in lymphoid tissues was not impaired in
the absence of LC migration, further studies demonstrated
that scrapie susceptibility was not reduced in mice with blocked
LC migration. When challenged with scrapie by skin scarifica-
tion, CD40L/ mice succumbed to clinical disease with a
significantly shorter incubation period than wild-type mice
(Table 2). The shortened incubation period in CD40L/ mice
was unexpected since a similar affect on scrapie pathogenesis
was not observed after inhibition of LC migration by topical
treatment with a caspase-1 inhibitor (Table 1). CD40 signaling
on neurons has been shown to play a physiological role in
promoting neuronal maintenance and survival (50). Thus, the
shortened scrapie incubation period observed in peripherally
inoculated CD40L/ mice might have been due to an in-
creased susceptibility of CD40L-deficient neurons to TSE-in-
duced neurodegeneration. After inoculation of wild-type and
CD40L/ mice with scrapie directly into the CNS (i.c. injec-
tion), all mice developed clinical disease with similar incuba-
tion periods. Furthermore, the pathological targeting of the
TSE-induced vacuolation (Fig. 3), PrPSc accumulation, or gli-
osis within the brain was not significantly different between
mouse strains, although microglia activation appeared to be
more pronounced in CD40L/ mice. Despite this apparent
increase in microglia activation, the magnitude and distribu-
tion of the disease-specific vacuolation in 12 different brain
regions were similar between CD40L/ and wild-type mice.
These data therefore demonstrate that the CD40-CD40L sig-
naling pathway does not play a critical role in the cerebral
pathogenesis of ME7 scrapie. Therefore, the shortened incu-
bation period observed in peripherally inoculated CD40L/
mice was most likely due to the absence of a CD40L-depen-
dent mechanism in the periphery, which may be involved in
impeding scrapie pathogenesis. It may also be possible that
CD40L deficiency affects the permeability of peripheral neu-
rons to TSEs influencing uptake and neuroinvasion.
In contrast to data described in the present study, a recent
report suggests the CD40-CD40L signaling pathway is involved
in the development and progression of CNS disease after in-
oculation with the 139A scrapie strain (8). In that study,
CD40L/ mice inoculated with 139A scrapie directly into the
CNS (i.c. injection) succumbed to disease 40 days earlier than
did wild-type control mice. Congruent with the findings in our
study, no significant differences in the extent of disease-specific
PrP-deposition or GFAP-expressing astrocytes were detected
in the brains of CD40L/ and wild-type mice, although mi-
croglia activation appeared to be more pronounced in
CD40L/ mice. However, the magnitude of the disease-asso-
ciated vacuolation detected in the brains of CD40L/ mice
was also more pronounced than in wild-type mice (8). This is in
contrast to data from our studies in which the magnitude and
distribution of the pathological targeting of the vacuolation in
CD40L/ mice were remarkably similar to the findings in
wild-type mice after inoculation either directly into the CNS
(i.c.) or via the skin (Fig. 3). In wild-type mice the distribution
and magnitude of the pathological targeting of the vacuolation
within the brain differs significantly between the 139A and
ME7 scrapie strains: for example, the 139A scrapie strain in-
duces stronger vacuolation in white matter. Therefore, these
two studies, considered together, suggest that it is possible that
the effects of CD40L on scrapie pathogenesis within the brain
are strain dependent.
CD40-CD40L interactions have a diverse range of activities
within the immune system, and further studies are necessary to
determine the precise effect of the blockade of this signaling
pathway on peripheral pathogenesis of ME7 scrapie. Apart
from a lack of PNA-binding germinal centers (58), there was
little evidence of disrupted lymphoid architecture in the lym-
phoid tissues of CD40L/ mice. Thus, the reduced incubation
period was unlikely to be due to effects on lymphoid architec-
ture, such as the repositioning of splenic FDCs in close asso-
ciation with peripheral nerves as recently shown in mice defi-
cient in the CXCR5 chemokine receptor (42). CD40-CD40L
interactions provide important signals for optimal macrophage
activation, and CD40L deficiency increases susceptibility to
certain intracellular pathogens (9, 36, 48). For example, mac-
rophages from Leishmania amazonensis-infected CD40L/
mice contain high parasite burdens and are unable to effec-
tively control the parasitemia (48). Since previous studies sug-
gest that macrophages may sequester and destroy scrapie in-
fectivity (4, 10, 11), it is reasonable to speculate that in the
absence of CD40-CD40L signaling in CD40L/ mice the
clearance of scrapie infectivity by cells such as macrophages is
likewise inhibited. For example, studies from Prinz et al. (43)
demonstrate that, in the absence of TNF receptor 1 signaling,
scrapie replication can occur in macrophages. Following uptake
by DCs, antigens rapidly enter the lysosomal compartment,
where they are broken down into peptides for presentation to
lymphocytes in association with major histocompatibility com-
plex class II (2). A recent study suggests that DCs may handle
TSE agents in a similar manner, since bone marrow-derived
DCs are able to process and degrade PrPSc after in vitro ex-
posure (30). Our studies also show that in vitro-cultivated
XS106 LC-like cells have the potential to acquire and degrade
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PrPSc. Another interpretation of these observations may be
that, after the uptake of PrPSc by XS106 LC-like cells, subse-
quent processing and/or catabolism of PrPSc masks the 8H4
epitope. However, whatever the effects of XS106 cells on PrPSc
were, further experiments confirmed that this was not a prop-
erty of all in vitro-cultivated cell lines since the highly imma-
ture cell line XS52 was unable to degrade PrPSc. Thus, these
data suggest that highly efficient antigen-processing LCs might
be impeded in processing scrapie in CD40L-deficient mice.
Inhibition of CD40L-dependent clearance mechanisms might
allow infectivity to accumulate earlier in draining lymphoid
tissue, shortening the disease incubation period. Treatments
that modulate this CD40L-dependent protective mechanism
might provide an effective therapeutic strategy for early inter-
vention in TSE pathogenesis.
The data presented here suggest that LCs are not involved in
the transportation of scrapie from the skin to lymphoid tissues.
However, these data do suggest that a CD40-CD40L-depen-
dent mechanism is involved in impeding scrapie neuroinvasion.
The precise mechanism by which scrapie infectivity is trans-
ported from the skin to lymphoid tissues remains to be iden-
tified. Since macrophages are most likely involved in the deg-
radation of infectivity (4, 10, 11), it is possible that scrapie
infectivity is transported in a cell-free manner. Soon after en-
tering the host antigens are rapidly opsonized by complement
components. Recent research has shown that complement
components play an important role in the localization of
scrapie to lymphoid tissues (28, 31), suggesting TSE agents
might be delivered to lymphoid tissues as cell-free comple-
ment-bound complexes. Understanding the earliest peripheral
mechanisms involved in the transportation or degradation of
scrapie will be important in the development of therapeutic
strategies to combat these fatal neurodegenerative diseases.
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